Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
10/2002
10/31/2002WO2002085336A1 Orodispersible effervescent tablets
10/31/2002WO2002085327A2 Use of nsaids for prevention and treatment of cellular abnormalities of the female reproductive tract
10/31/2002WO2002085302A2 Methods of treating intestinal inflammation
10/31/2002WO2002085299A2 Therapeutic treatments using the direct application of antimicrobial metal compositions
10/31/2002WO2002085291A2 Nociceptin analogs
10/31/2002WO2002085123A1 Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
10/31/2002WO2002068390A8 Diamides which inhibit tryptase and factor xa activity
10/31/2002WO2002068381A3 Aryl-n-cyanoguanidines and methods related thereto
10/31/2002WO2002066681A9 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors
10/31/2002WO2002066650A3 Streptococcus pyogenes polypeptides and corresponding dna fragments
10/31/2002WO2002060949A3 Glycoforms a fas ligand inhibitory protein analog
10/31/2002WO2002055547A9 Sfrp and peptide motifs that interact with sfrp and methods of their use
10/31/2002WO2002053185A3 Anti-inflammatory use of polycationic compounds
10/31/2002WO2002049650A3 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives
10/31/2002WO2002026217A3 Composition for the transdermal delivery of fentanyl
10/31/2002WO2002022611A3 Caspase inhibitors and uses thereof
10/31/2002WO2002014499A3 Claudin polypeptides
10/31/2002WO2002010392A3 Mammalian dna binding membrane-associated protein-encoding gene and uses
10/31/2002WO2002004002A3 Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals
10/31/2002WO2001087348A3 Multifunctional nanodevice platform
10/31/2002WO2001044243A3 Novel heteroaryl-diazabicycloalkanes
10/31/2002WO2000062766A3 Uses of ppar-gamma agonists in neutrophil-induced diseases
10/31/2002US20020161262 Use treating various medical conditions, including pain
10/31/2002US20020161237 (Z)-2-((2-bromo-4-(((3-hydroxybenzyl)amino)carbonyl)benzoyl) -amino)pent-2-enoic acid, for example; useful for treating psoriasis
10/31/2002US20020161221 Ether type lipid a 1-carboxylic acid analogs
10/31/2002US20020161169 Hydrogel-forming system with hydrophobic and hydrophilic components
10/31/2002US20020161053 Inflammatory cytokine production inhibitors, matrix metalloprotease production inhibitors, inflammatory cell adhesion molecules incidence inhibitors, antiinflammatory agents
10/31/2002US20020161051 For alleviating chronic pain and allodynia and have no or only minimal cardivascular and/or sedatory activity
10/31/2002US20020161047 Method for preventing and treating visceral pain and gastrointestinal disorders
10/31/2002US20020161042 Nitric oxide donor composition and method for treatment of anal disorders
10/31/2002US20020161033 Substituted 1,5-dihydropyrrol-2-one derivatives active as NMDA receptor antagonists for treatment of states of pain
10/31/2002US20020161025 N-substituted indole-3glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action
10/31/2002US20020161024 Administering 2-(piperidin-2,6-dion-3-yl),4-amino-isoindolin-1-one to treat an eye condition
10/31/2002US20020161019 For treatment of depression, anxiety, feeding disorders, headache, drug addiction, inflammatory disorders
10/31/2002US20020161014 Purinyl substituted quinazoline-4-one derivatives
10/31/2002US20020161010 Treatment of various disorders associated with enhanced activity of kinase p38-alpha and/or transforming growth factor beta; antiinflammatory agents
10/31/2002US20020161006 1,4-dihydropyridine compounds as bradykinin antagonists
10/31/2002US20020161005 Nitrogen heterocycle compounds
10/31/2002US20020161004 Antiinflammation agents
10/31/2002US20020161000 Treating diseases resulting from tissue breakdown such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, atherosclerosis, and osteoporosis
10/31/2002US20020160987 Novel 4-dedimethylaminotetracycline derivatives
10/31/2002US20020160974 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
10/31/2002US20020160965 Cosmetic and dermatological formulations comprising flavonoids
10/31/2002US20020160963 Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists
10/31/2002US20020160948 Such as preventing or treating primary cancer cell growth
10/31/2002US20020160943 Tumor-activated prodrug compounds and treatment
10/31/2002US20020160940 Modulation of endogenous gene expression in cells
10/31/2002US20020160484 Central nervous system disorders therapy; genetic engineering
10/31/2002US20020160478 Short peptides which selectively modulate the activity of protein kinases
10/31/2002US20020160477 CAF1-related protein
10/31/2002US20020160438 Modulate kinase; antiinflammatory agents; respiratory system disorders
10/31/2002US20020160415 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer and for the prevention of cancer in at- risk subjects
10/31/2002US20020160059 Treatment of urogenital disorders, menstrual cramps
10/31/2002US20020160043 Dissolvable drug-containing dosage form for use in transmucosal delivery of drug to patient, comprising binding agent formed into solid matrix dissolvable in mouth, pharmacologically effective dosage of drug, buffer
10/31/2002US20020160010 Use of preparations containing anti-cd44 antibodies in the treatment of certain tumours and the suppression of immune reactions
10/31/2002US20020160000 PD-1, a receptor for B7-4, and uses therefor
10/31/2002US20020159973 Administering to the patient at least one statin (HMG-Coa-reductase inhibitor) in an amount effective to modulate MHC class II (Major Histocompability complex) or CD/40(antigen) expression in the patient
10/31/2002US20020159956 Providing a chewing gum, includes a gum center and a coating coverings, coating includes a drug designed to be delivered into systemic system of indivisual
10/31/2002CA2483507A1 Enzyme and snp marker for disease
10/31/2002CA2445888A1 Chiral, broad-spectrum antibacterial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation and compositions
10/31/2002CA2445740A1 Use of metals to treat inflammatory skin conditions
10/31/2002CA2445734A1 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue
10/31/2002CA2445729A1 Use of metals to treat mucosal membranes
10/31/2002CA2445508A1 Agent for topical ophthalmic treatment of ocular inflammatory diseases
10/31/2002CA2445255A1 Vhh single heavy chain antibody and a method for its preparation in a mammal
10/31/2002CA2445233A1 Phthalazinones derivatives useful as pde4/7 inhibitors
10/31/2002CA2445202A1 Method for evaluating the efficacy of treatment with bacterial dna and bacterial cell walls
10/31/2002CA2445188A1 Arylindenopyridines with pde inhibiting activity
10/31/2002CA2444885A1 Methods and compositions for treating oral and esophageal lesions
10/31/2002CA2444675A1 Secreted proteins
10/31/2002CA2444599A1 Melanocortin receptor ligands
10/31/2002CA2444235A1 New polynucleotides and polypeptides of the ifn.alpha.-17 gene
10/31/2002CA2443944A1 Agent for prophylaxis or treatment of inflammatory diseases in mucosa of oral cavity and the like
10/31/2002CA2443935A1 Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
10/31/2002CA2443600A1 Heterocyclyldicarbamides as caspase inhibitors
10/31/2002CA2443587A1 Therapeutic treatments using the direct application of antimicrobial metal compositions
10/31/2002CA2443373A1 New polynucleotides and polypeptides of the erythropoietin gene
10/31/2002CA2438833A1 Lactic acid bacteria as agents for treating and preventing allergy
10/30/2002EP1252893A1 Medicine containing anemonin as effective component for treating aseptic inflammation
10/30/2002EP1252883A1 Process for reducing partially or completely the symptoms associated with the histamin release within the human body
10/30/2002EP1252333A2 Methods and materials relating to cd84-like polypeptides and polynucleotides
10/30/2002EP1252298A2 Phosphodiesterases
10/30/2002EP1252188A2 G-protein coupled receptors
10/30/2002EP1252179A2 High purity lipopeptides, lipopeptide micelles, processes for preparing same and pharmaceutical compositions containing them
10/30/2002EP1252177A1 Ligand for vascular endothelial growth factor receptor
10/30/2002EP1252170A2 Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
10/30/2002EP1252164A1 Method for producing 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1h-pyrrolizine-5-yl acetic acid
10/30/2002EP1252163A2 4-pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy
10/30/2002EP1252162A1 Alpha v integrin receptor antagonists
10/30/2002EP1252158A1 Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes
10/30/2002EP1252157A1 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
10/30/2002EP1252155A1 Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8 4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one
10/30/2002EP1252154A1 Heterocyclic amide derivatives
10/30/2002EP1252153A1 Substituted piperidines, medicaments containing these compounds, and methods for the production thereof
10/30/2002EP1252152A1 Urea compounds as inhibitors for vla-4
10/30/2002EP1252144A1 Substituted glutarimides and use thereof il-12 production inhibitors
10/30/2002EP1252143A1 Method for preparing alpha-sulfonyl hydroxamic acid derivatives
10/30/2002EP1252142A1 Indole derivatives as mcp-1 receptor antagonists
10/30/2002EP1252133A2 Pharmaceutical compounds
10/30/2002EP1251873A1 Antagonist of th-1 immuneresponse inducing cytokine for the treatment of autoimmune diseases
1 ... 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 ... 1272